Clinical Trials · us
Tradipitant reduces semaglutide-related vomiting in Phase 3 trial; benefits in routine use remain unclear
The incidence of vomiting fell from 58.5% to 43.0%, offering a new lead for improving the tolerability of GLP-1 therapies. However, the trial administered a single 1 mg dose of semaglutide directly, bypassing the gradual dose escalation commonly used in clinical practice, leaving a gap between the results and everyday prescribing.
For people using GLP-1 drugs, nausea and vomiting can make treatment difficult to continue. Vanda Pharmaceuticals announced on October 27 that oral tradipitant reduced semaglutide-induced vomiting in Phase 3 Study 3601, providing new evidence for addressing this treatment burden. However, the dosing approach used in the study also limits the applicability of the results.
In this randomized, placebo-controlled trial, 61 of 142 participants in the tradipitant group experienced vomiting, or 43.0%, compared with 96 of 164 participants in the placebo group, or 58.5%. The difference was 15.5 percentage points, representing a relative reduction of approximately 27%. The trial met its primary endpoint, with a study-center-adjusted p-value of 0.006. The measure here was whether vomiting occurred; it cannot be interpreted as a 27% reduction in the number of vomiting episodes for each person.
The trial also met a key secondary endpoint: participants who experienced vomiting and had a worst nausea score of at least 3 accounted for 33.1% and 50.6% of the two groups, respectively. The company also reported larger reductions in higher-burden outcomes, such as more than 10 total vomiting episodes, but these were post hoc exploratory analyses, and their evidentiary weight should be assessed separately from that of the prespecified endpoints.
The most important limitation is that all participants received a single 1 mg dose of semaglutide directly, without the gradual dose escalation commonly used in clinical practice. HCPLive’s coverage of the same event also noted this difference and cited company data showing that nearly all vomiting occurred before the end of the second day, with the largest differences between the groups on days one and two. The study therefore primarily demonstrates a short-term preventive effect under a stronger emetic stimulus. It cannot yet be used to directly estimate how much discomfort could be reduced during routine dose escalation or whether long-term treatment discontinuation rates could be lowered.
Tradipitant is a neurokinin-1 (NK-1) receptor antagonist that works by blocking central vomiting signals involving substance P. This provides a biological pathway for addressing vomiting alongside GLP-1 therapy, but this trial used semaglutide. Whether the effect can extend to other GLP-1 drugs cannot be determined from the mechanism alone.
On safety, Vanda said no new safety signals were observed. HCPLive’s reporting on efficacy and safety was likewise based on the company’s announcement and does not constitute separate independent validation. Neither source provided a complete breakdown of adverse events, so “no new signals observed” remains insufficient to answer questions about the safety of long-term combined use.
Vanda plans to discuss the data with the U.S. Food and Drug Administration (FDA) and submit a supplemental new drug application. The central questions ahead are whether this short-term trial evidence can support the proposed use and whether reducing vomiting can translate into practical benefits for treatment continuation in everyday care involving gradual dose escalation and repeated dosing.